Mirum Pharmaceuticals, Inc. (MIRM)

In March 2024, Mirum Pharmaceuticals' shares climbed after the FDA approved Livmarli for cholestatic pruritus in PFIC patients. In February 2025, the company reported its fourth quarter and year-end 2024 financial results and provided a business update. In May 2025, Mirum Pharmaceuticals reported its first quarter 2025 financial results and provided a business update. In August 2025, Mirum Pharmaceuticals reported its second quarter 2025 financial results and provided a business update. In October 2025, the company announced an update on its ongoing Phase 2 clinical study for MRM-3379 in Fragile X Syndrome and a Phase 3 clinical study on maralixibat for cholestatic pruritus.

The provided information does not explicitly detail demand seasonality for Mirum Pharmaceuticals' products and services. However, as a biopharmaceutical company focused on rare and life-threatening diseases, the demand for its medications is likely driven by patient diagnoses and medical necessity rather than typical seasonal fluctuations.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and debilitating liver diseases, particularly in children and adults. Its major products include LIVMARLI (maralixibat) oral solution, approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), VOLIXIBAT, an IBAT inhibitor in development for adult cholestasis, and CHENODAL, used for cerebrotendinous xanthomatosis and cholestasis inborn errors of bile acid metabolism. The company is also conducting clinical trials for MRM-3379 in Fragile X Syndrome and maralixibat in cholestatic pruritus.

Mirum Pharmaceuticals is headquartered in Foster City, California, US. The company primarily operates in the US, with its lead product, Livmarli, having received approvals in the US, Europe, Canada, and other regions globally.

Mirum Pharmaceuticals maintains a strong reputation in the niche market of rare cholestatic liver diseases, positioning itself as a leader in developing therapies, particularly for pediatric populations. The FDA approval of Livmarli for PFIC in March 2024 validated the company's research and development efforts and provided a foundation for commercial growth. Strong market uptake of Livmarli and increased investment in R&D underscore the company's strengths and commitment to addressing unmet medical needs. Ongoing clinical trials for maralixibat in cholestatic pruritus and MRM-3379 in Fragile X Syndrome demonstrate a commitment to expanding its portfolio and addressing new therapeutic areas.

Major institutional owners of Mirum Pharmaceuticals, Inc. include Frazier Life Sciences Management, Henderson Group, BlackRock, BVF, Eventide Asset Management, Vanguard Group, Novo A/S, Citadel Advisors, State Street Corporation, Tang Capital Management, Polar Capital Holdings, Geode Capital Management, ClearBridge Advisors, Rock Springs Capital Management, Pictet Asset Management Holding SA and UBS O'Connor.